| Trial ID: | L0265 |
| Source ID: | NCT01111630
|
| Associated Drug: |
Recomon (Epoetin Beta)
|
| Title: |
Study of Erythropoietin (EPO) Administration Schedule
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Renal Failure|Anaemia
|
| Interventions: |
DRUG: recomon (Epoetin Beta)|DRUG: recomon (Epoetin Beta)
|
| Outcome Measures: |
Primary: The hemoglobin variability between once & three times weekly administration, 24 weeks | Secondary: The hematocrit variability between once & three times weekly administration, 24 weeks|Mean value of Hb and Hct between once & three times weekly administration, 24 weeks|Drop out rate during dose fix period, 24 weeks|Mean value of Hb and Hct during dose fix period, 24 weeks|Variability of Hb and Hct during dose fix period, 24weeks|Weekly oetin-beta maintenance dose between once & three times weekly administration, 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: JW Pharmaceutical
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-10
|
| Completion Date: |
2014-01
|
| Results First Posted: |
|
| Last Update Posted: |
2014-05-14
|
| Locations: |
NHIC Ilsan Hospital, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01111630
|
